BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25410892)

  • 1. Genetic variation in Otos is associated with cisplatin-induced ototoxicity.
    Spracklen TF; Whitehorn H; Vorster AA; Ramma L; Dalvie S; Ramesar RS
    Pharmacogenomics; 2014 Sep; 15(13):1667-76. PubMed ID: 25410892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
    Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
    Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity.
    Cooper LB; Chan DK; Roediger FC; Shaffer BR; Fraser JF; Musatov S; Selesnick SH; Kaplitt MG
    Otol Neurotol; 2006 Jun; 27(4):484-90. PubMed ID: 16791039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenoviral-mediated up-regulation of Otos, a novel specific cochlear gene, decreases cisplatin-induced apoptosis of cultured spiral ligament fibrocytes via MAPK/mitochondrial pathway.
    Zhuo XL; Wang Y; Zhuo WL; Zhang YS; Wei YJ; Zhang XY
    Toxicology; 2008 Jun; 248(1):33-8. PubMed ID: 18403086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms.
    El Charif O; Mapes B; Trendowski MR; Wheeler HE; Wing C; Dinh PC; Frisina RD; Feldman DR; Hamilton RJ; Vaughn DJ; Fung C; Kollmannsberger C; Mushiroda T; Kubo M; Gamazon ER; Cox NJ; Huddart R; Ardeshir-Rouhani-Fard S; Monahan P; Fossa SD; Einhorn LH; Travis LB; Dolan ME
    Clin Cancer Res; 2019 Jul; 25(13):4104-4116. PubMed ID: 30952644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research protocol: Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program.
    Paken J; Govender CD; Sewram V
    BMC Womens Health; 2017 Dec; 17(1):129. PubMed ID: 29228931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
    Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
    J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the protective effects of intratympanic dexamethasone and methylprednisolone against cisplatin-induced ototoxicity.
    Özel HE; Özdoğan F; Gürgen SG; Esen E; Genç S; Selçuk A
    J Laryngol Otol; 2016 Mar; 130(3):225-34. PubMed ID: 26830667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ototoxicity of cisplatin in children with malignant diseases].
    Hadjilaskari P; Fengler R; Hartmann R; Henze G
    Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma.
    Brown AL; Lupo PJ; Okcu MF; Lau CC; Rednam S; Scheurer ME
    Cancer Med; 2015 Nov; 4(11):1679-86. PubMed ID: 26400460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity.
    Waissbluth S; Daniel SJ
    Hear Res; 2013 May; 299():37-45. PubMed ID: 23467171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
    Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
    J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of cisplatin ototoxicity and progress in otoprotection.
    Rybak LP
    Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):364-9. PubMed ID: 17823555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxytocin as a protective agent in cisplatin-induced ototoxicity.
    Bekmez Bilmez ZE; Aydin S; Şanli A; Altintoprak N; Demir MG; Atalay Erdoğan B; Kösemihal E
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):875-9. PubMed ID: 26865281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
    Paken J; Govender CD; Pillay M; Feyasa M; Sewram V
    PLoS One; 2023; 18(4):e0283639. PubMed ID: 37014872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic background of cisplatin induced ototoxicity].
    Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
    Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
    Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
    Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.